GSK plc, a British multinational pharmaceutical and biotechnology company, has agreed to pay $2.2 billion USD to settle around 80,000 Zantac lawsuits in the United States.
According to reports, the discontinued version of Zantac, a popular heartburn medication, was pulled due to fears that a key ingredient, ranitidine, could turn into a substance that may cause cancer when exposed to heat. This settlement accounts for 93% of all cases.
The report further mentions that GSK will also pay $70 million USD to settle a complaint by a laboratory that the drug maker defrauded the US government by concealing Zantac’s cancer risks. The company did not admit wrongdoing in any of the cases.
